OOIR: Observatory of International Research

Papers

(The H4-Index of Vaccine is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003–2024)	223
Editorial Board/Aims and Scope	204
Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS coloni	174
Editorial Board/Aims and Scope	152
Managing multiplicity in clinical vaccine studies – A case study using a gatekeeping testing strategy	151
Editorial Board/Aims and Scope	130
Tackling the burden of mumps in the military: A report of the Defense Health Board	116
Humoral and cellular immune responses induced by serogroup W135 meningococcal conjugate and polysaccharide vaccines	116
TAK − 021, an inactivated Enterovirus 71 vaccine candidate, provides cross-protection against heterologous sub-genogroups in human scavenger receptor B2 transgenic mice	106
Issues with infectious disease vaccine introduction into routine vaccination in Japan, and considerations for accelerating the process	102
Pediatric otitis media in Japan: A nationwide longitudinal study of the pre- and post-pneumococcal conjugate vaccine eras born in 2001 and 2010	99
COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants	96
A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years an	95
Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study	95
“Every interaction you have …should be an opportunity to discuss and offer influenza vaccination”. Health service perspectives on influenza vaccination promotion and delivery to Aboriginal families li	93
Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination	93
Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys	93
Editorial Board/Aims and Scope	83
Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants	83
Erratum to “Motivational interviewing and vaccine acceptance in children: The MOTIVE study” [Vaccine 40(12) (2022) 1846–1854]	82
Erratum to “Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals” [Vaccine 41(37) (2023) 5469-5476]	80
Corrigendum to ‘Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice’ [Vaccine 39 (2021) 6213–6220]	80
Corrigendum to “Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis” [Vaccine 40(41) (2022) 5971	79
Humoral immune response profile of a cattle herd vaccinated with 5- and 10-times Bakirköy strain sheep pox vaccine under field conditions	77
Cost-effectiveness of anti-viral treatment for infants with RSV disease in the United Kingdom	77

Evaluation of dynamics of immune responses and protective efficacy in piglets immunized with an inactivated porcine reproductive and respiratory syndrome vaccine candidate	76
Effectiveness of the varicella vaccine in the real world, a matched case-control study	75
Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study	72
Stability studies for the identification of critical process parameters for a pharmaceutical production of the Orf virus	71
Compliance, procrastination and refusal: American COVID-19 vaccination trust and value orientation	71
Long-term impact of rotavirus vaccination on all-cause and rotavirus-specific gastroenteritis and strain distribution in Central Kenya: An 11-year interrupted time-series analysis	69
Evaluating concurrency and gaps between self-report and vaccine card data for COVID-19 vaccination	69
Pneumonia hospitalization after introduction of pneumococcal conjugate vaccine in Japan: Descriptive study using a nationwide claims database	69
The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana	68
Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations	67
UK healthcare professionals’ attitudes towards the introduction of varicella vaccine into the routine childhood vaccination schedule and their preferences for administration	66
Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea	66
Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England	65
Vaccination during febrile illness, what do we know? A systematic-narrative hybrid review of the literature and international recommendations	61
Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines	61
World Health Organization Expert Working Group: Recommendations for assessing morbidity associated with enteric pathogens	59
Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink	58
Determinants of immunization in polio super high-risk union councils of Pakistan	58
Cost of illness due to pertussis in adults ≥50 years of age in the United Kingdom	58
Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up	58
Epidemiological characteristics and serotype distribution of culture-confirmed pediatric pneumococcal pneumonia before and after PCV 10 introduction, a multicenter study in Bogota, Colombia, 2008–2019	57
Participant-reported neurological events following immunization in the Canadian National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study	56
Why did Brazil fail to vaccinate children against COVID-19 during the pandemic? An assessment of attitudinal and behavioral determinants	55
Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental chal	55
Expected endpoints from future chikungunya vaccine trial sites informed by serological data and modeling	55
The methodological quality of economic evaluations of measles outbreaks: A systematic review of cost-of-illness studies	54
COVID-19 and seasonal flu vaccination hesitancy: Links to personality and general intelligence in a large, UK cohort	54
Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2	53